ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2
NCT05463289
Recruiting
The purpose of this study is to determine if use of a nonmydriatic fundus camera using autonomous artificial intelligence software at the point of care increases the proportion of underserved youth with diabetes screened for diabetic retinopathy.
Gender:
ALL
Ages:
Between 8 years and 21 years
Trial Updated:
02/13/2025
Locations: Johns Hopkins Pediatric Diabetes Center, Baltimore, Maryland
Conditions: Type 1 Diabetes, Type 2 Diabetes, Cystic Fibrosis-related Diabetes
Register for Updates
Migraine in Adolescents
NCT05654012
Recruiting
Aim 1. To identify psychophysical and neural factors predicting migraine onset in adolescents Aim 2a. To determine hormonal, psychophysical, and neural changes associated with migraine onset. Aim 2b. To identify the temporal relationships between hormonal, psychophysical, and neural changes preceding vs. following migraine onset. Aim 3. To identify psychophysical and neural factors predicting migraine prognosis in adolescents with migraine.
Gender:
ALL
Ages:
Between 10 years and 13 years
Trial Updated:
02/13/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Migraine
Register for Updates
REBYOTA™ Prospective Registry
NCT05835219
Recruiting
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA™ is at the treating physician's discretion and independent from the decision to enroll the patient in the study. Data will be collected from patients' medical records after obtaining informed consent. Data about clinical history, CDI events (prim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Ferring Investigational Site, Chandler, Arizona +41 locations
Conditions: Recurrence of Clostridium Difficile Infection
Register for Updates
A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms
NCT06034002
Recruiting
This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered in participants with myeloproliferative neoplasms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: City of Hope Medical Center, Duarte, California +13 locations
Conditions: Myeloproliferative Neoplasms
Register for Updates
A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
NCT06213831
Recruiting
This study is being conducted to determine the safety and tolerability of ruxolitinib 1.5% cream under maximal use conditions in participants with Prurigo Nodularis (PN).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/13/2025
Locations: Saguaro Dermatology, Phoenix, Arizona +20 locations
Conditions: Prurigo Nodularis
Register for Updates
The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy
NCT06318507
Recruiting
This study will determine how the intestinal microbiome differs between patients with obesity and early triple-negative breast cancer who achieve a pathologic complete response from preoperative anti-PD-1 immunotherapy (pembrolizumab) versus patients who do not.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Pennington Biomedical Research Center, Baton Rouge, Louisiana
Conditions: Breast Neoplasms
Register for Updates
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
NCT06465953
Recruiting
This study will enroll participants with myelodysplastic syndromes (MDS) with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have not received treatment with a hypomethylating agent previously. Participants will be randomized to receive either ivosidenib (IVO) alone or azacitidine (AZA) alone. IVO will be administered daily throughout the 28-day treatment cycle and AZA will be administered for the first 7 days of each 28-day cycle. Study visits will be conducted every week during Cy... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: University of Chicago, Duchossois Center for Advanced Medicine (DCAM), Chicago, Illinois +20 locations
Conditions: Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)
Register for Updates
Telehealth Intervention for Improving Distress and Financial Toxicity in the Caregivers
NCT06709404
Recruiting
This clinical trial assesses whether resource identification for primary caregivers can affect financial stress, quality of life, depression, and the general belief in the ability to cope with daily life. Caregivers of patients receiving cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CS+HIPEC) demonstrate that they endure high depressive symptom burdens and financial distress. Further, they experience symptom trajectories that differ from those of patients. In short, they r... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Register for Updates
Milieu Teaching-AV (MT-AV Pilot)
NCT06794476
Recruiting
This project will look at whether a novel approach to language intervention that encourages looking to audiovisual speech cues for infants with autistic older siblings (Baby Sibs), who are highly likely be diagnosed with autism or developmental language disorder (DLD). This study will specifically look at (a) whether caregivers find this approach to be easy to implement in their homes, (b) whether they find this approach to be acceptable, and (c) whether caregivers use the taught strategies in i... Read More
Gender:
ALL
Ages:
Between 5 months and 12 months
Trial Updated:
02/13/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Autism Sibling, Autism Spectrum Disorder
Register for Updates
Suicidal Behavior in Patients Diagnosed with Bipolar Disorder
NCT02604277
Recruiting
The purpose of this study is to learn the environmental and psychological factors that impact suicidality in patients diagnosed with Bipolar Disorder. Additionally, the study aims to identify treatments to reduce the suicidal behavior and improve quality of life through a 6-week group-based intervention program.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
02/13/2025
Locations: Grady Health System, Atlanta, Georgia
Conditions: Depression, Alcoholism, Drug Abuse
Register for Updates
Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules
NCT04171492
Recruiting
This study evaluates the how addition of the Nodify XL2 test result impacts the clinical management of newly identified solid lung nodules assessed as low to moderate risk of cancer.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/13/2025
Locations: University of Colorado, Aurora, Colorado +25 locations
Conditions: Nodule Solitary Pulmonary, Non-small Cell Carcinoma
Register for Updates
Non-Invasive Brain Stimulation to Control Large-Scale Brain Networks
NCT04680481
Recruiting
This project will assess the feasibility of traveling wave transcranial alternating current stimulation (tACS) to modify working memory performance and large-scale brain connectivity in surgical epilepsy patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Working Memory
Register for Updates